None listed
Conditions
Interventions
Each subjects consumed HK1502 that are solid preparations blended with vitamin for 8 continuous weeks.
Sponsors
Kojinkai, Association of Medical Corporation Hosui General Medical Clinic.
Health Sciences Research Institute, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Subjects(japanese male and female) who are able to show their willingness of participating to the clinical trial, and who are able to obtain written consent to participate in the clinical trial after understanding explanation of the clinical trial. 2)Subjects who aged 35 years-old to 65 years-old. 3)BMI 18.5 more. 4)Subjects who are not regularly consuming supplements that are some possibility of having a negative influence on the clinical trial, or who are able to stop the supplements from two weeks before the clinical trial start to the end of the clinical trial. 5)The right hand is dominant hand.
Exclusion criteria
Exclusion criteria: 1)Subjects who suffer any disease at present and who are going to take continuous medical treatments during the clinical trial, or who are going to use the over-the-counter drug. 2)Subjects who have trauma on the middle fingertip of the left hand, and who have a negative influence on the skin AGE fluorometry. 3)Subjects who have hypersensitivity or allergic reaction to a certain drug medicine or food. 4)Subjects who have an operation career such as hepatectomy, gastrectomy, gastrointestinal suturesin, intestinal resection, transplanting and others in a digestive organ. 5)Subjects who have impaired respiratory and cardiovascular organ. 6)Subjects with experience of alcoholism, or who drink liquor excessively(pure alcohol conversion : over-60g per day). 7)Subjects who have participated in other clinical trials and use tests that apply foods and others within the last 12 weeks prior to the current clinical trial. 8)Subjects who apply to the following. (1)Male subjects who donated 400ml of blood within the last 12 weeks prior to the current clinical trial. In female, within the last 16 weeks. (2)Subjects who donated 200ml of blood within the last 4 weeks prior to the current clinical trial. (3)Subjects who donated components of blood such as blood platelet and blood plasma within the last 2 weeks prior to the current clinical trial. (4)Subjects who have had experiences of a blood collecting conforming to the above matters. 9)Subjects who are the pregnant or breast-feeding woman. 10)Subjects who are planning to become the pregnant woman during the clinical trial. 11)Others who have been determined ineligible or undesirable by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| *Skin AGE fluorometry *Doctor's findings such as subjective or objective symptoms and medical observations after the clinical trial start | — |
Secondary
| Measure | Time frame |
|---|---|
| *Questionnaire survey(five-point scale) *Physical examinations such as height, body weight, blood pressure and others *Subject diary(doctor's findings such as expression presence or absence of adverse events) | — |
Countries
Japan
Contacts
Public ContactYukiyoshi Katsumata
Derma Labo, inc. headquarter
Outcome results
None listed